يعرض 1 - 15 نتائج من 15 نتيجة بحث عن '"Pedro Eerdmans"', وقت الاستعلام: 0.54s تنقيح النتائج
  1. 1

    المساهمون: University of Catania [Italy], Hôpital Privé Jacques Cartier [Massy], The University of Florida College of Medicine, Harvard Medical School [Boston] (HMS), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), DEKRA CONSULTING GMBH STUTTGART DEU, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), McMaster University [Hamilton, Ontario], Technical University of Munich (TUM)

    المصدر: Journal of the American College of Cardiology
    Journal of the American College of Cardiology, Elsevier, 2020, 76 (12), pp.1468-1483. ⟨10.1016/j.jacc.2020.06.085⟩
    Journal of the American College of Cardiology, 2020, 76 (12), pp.1468-1483. ⟨10.1016/j.jacc.2020.06.085⟩

  2. 2
  3. 3
  4. 4

    المساهمون: Hôpital de la Tour, Cardiovascular Research Foundation, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Florida [Gainesville] (UF), University of Catania [Italy], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Timone [CHU - APHM] (TIMONE), Harvard Medical School [Boston] (HMS), AUTRES, McMaster University [Hamilton, Ontario], U.S. Food and Drug Administration (FDA), London School of Hygiene and Tropical Medicine (LSHTM), Lukaskrankenhaus, Uppsala University, Seoul National University Hospital, Kyoto University, Pharmaceuticals and Medical Devices Agency, Columbia University [New York], National University of Ireland [Galway] (NUI Galway), Scripps Clinic [San Diego, CA, USA], Duke Clinical Research Institute, Duke University Medical Center, Erasmus University Medical Center [Rotterdam] (Erasmus MC), University of Bern, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cardiovascular European Research Center, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Hôpital Privé Jacques Cartier [Massy], The ARC-HBR group was entirely funded by multiple industry sponsors. Sponsors participated as observers in both meetings and were provided a copy of the document before submission. The contributing companies were Abbott Vascular, Alvimedica, Amgen, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Celonova, Chiesi, Cordis, Daiichi Sankyo, Edwards Lifesciences, Janssen, Medinol, Medtronic, Orbusneich, Portola, Sanofi, Sinomed, Sahajanand Medical Technologies, and Terumo.Conflict of interest: Dr Colleran received financial compensation for her contribution to the preparation of this document. In accordance with the ARC charter, none of the other participants received fees or honoraria for their participation in the meetings or their contribution to this document. Dr Urban reports receiving speaker and consulting honoraria as an individual from Biosensors-Europe, Sinomed, and Terumo, participating in paid review activities (Clinical End Point Committee, Data Safety Monitoring Board) for Edward Lifesciences, Terumo, and Abbott Vascular, and serving as a medical codirector at the Cardiovascular European Research Center, a contract research organization based in Massy, France. Dr Mehran reports consultant fees to the institution from Abbott Laboratories and Spectranetics/Philips/Valcano Corp, consulting fees from Boston Scientific, Cardiovascular Systems Inc, Medscape, Siemens Medical Solutions, Regeneron Pharmaceuticals Inc, Roivant Sciences Inc, and Sanofi, being the spouse of a consultant for Abiomed and The Medicines Company, research funding to the institution from AstraZeneca, Bayer, Beth Israel Deaconess Hospital, BMS, CSL Behring, Eli Lilly and DSI, Medtronic, Novartis Pharmaceuticals, and Orbus Neich, scientific advisory board fees from PLx Opco Inc, dba PLx Pharma Inc, scientific advisory board fees to the institution from Bristol-Myers Squibb, executive committee fees from Janssen Pharmaceuticals and Osprey Medical, speaker engagements for Abbott Laboratories, equity from Claret Medical and Elixir Medical, and Data Safety Monitoring Board fees to the institution from Atermark Research Partners. Dr Angiolillo reports payments, consulting fees, or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PLx Pharma Inc, Pfizer, Sanofi, and The Medicines Company, fees for participation in review activities from CeloNova and St. Jude Medical, institutional grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey Medical, and Renal Guard Solutions, and funding from the Scott R. MacKenzie Foundation and the National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award to the University of Florida UL1 TR000064 and National Institutes of Health/National Human Genome Research Institute U01 HG007269. Dr Byrne reports lecture fees from B. Braun Melsungen AG, Biotronik, Boston Scientific, and Micell Technologies and research funding to the institution from Boston Scientific and Celonova Biosciences. Dr Capodanno reports personal fees from Abbott Vascular, Bayer, Daiichi Sankyo, Pfizer, and AstraZeneca. Dr Cutlip reports receiving consultant fees from Celonova Biosciences and academic salary support from the Baim Institute for Clinical Research, an academic research organization in Boston, MA. Dr Eikelboom reports consulting fees and grant support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis. Dr Gibson reports being chief executive officer of the Baim Institute for Clinical Research, in addition to receiving research grant funding from Angel Medical Corp, Bayer Corp, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corp, and Portola Pharmaceuticals, consultant fees from Amarin Pharama, Amgen, Bayer Corp, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Cardiovascular Research Foundation, CSL Behring, Chiesi, Duke Clinical Research Institute, Eli Lilly and Company, Gilead Sciences, Inc, Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corp, The Medicines Company, MedImmune, Medtelligence, Merck & Co, Inc, Microport, Novo Nordisk, PERT Consortium, Pharma Mar, Portola Pharmaceuticals, Sanofi, Somahlution, Vereseon Corporation, and Web MD, and royalties as a contributor from UpToDate in Cardiovascular Medicine. Dr Gregson reports personal fees from Edwards Lifesciences, MvRX, Amarin Corp, and BioSensors. Dr Haude reports grant support from Biotronik, Orbus Neich, AbboF, Medtronic, and Cardiac Dimensions, speaker’s bureau fees from Biotronik, Orbus Neich, AbboF, Medtronic, Lilly, Philips/ Volcano, and Cardiac Dimensions (Proctor), and consultant fees from Biotronik, Orbus Neich, and AbboF. Dr James reports institutional research grants from AstraZeneca, Bayer, Jansen, The Medicines Company, Abbot Vascular, and Boston Scientific, as well as honoraria from AstraZeneca, Bayer, and Medtronic. Dr Kimura reports consulting fees or honoraria from Abbott Vascular Japan Co, Ltd, Kowa Co, Ltd, Kowa Pharmaceutical Co Ltd, Sanofi K.K., Nippon Boehringer Ingelheim Co, Ltd, and Bristol-Myers Squibb K.K., as well as grant support from Otsuka Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Mitsubishi Tanabe Pharma Corp, Takeda Pharmaceutical Co Ltd, and Nippon Boehringer Ingelheim Co, Ltd. Dr Leon reports receiving research grants from Abbott Vascular, Boston Scientific, Medtronic, Biosensors, and SinomedEquity-Medinol. Dr Mylotte reports speaker fees from Biosensors and institutional research grants from Biosensors and Medtronic. Dr Pocock has served on steering committees or data monitoring committees for trials sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Idorsia, Janssen, Medtronic, Novartis, Novo Nordisk, and Vifor, and has received grant funding from AstraZeneca and Merck. Dr Price reports receiving consulting honoraria from AstraZeneca, Chiesi USA, Medtronic, Boston Scientific, and Abbott Vascular/St Jude Medical, speaker’s bureau/fees from AstraZeneca, Chiesi USA, Medtronic, Boston Scientific, Abbott Vascular/St Jude Medical, and ACIST Medical, and institutional research grants from Daiichi-Sankyo. Dr Valgimigli reports grants and personal fees from Abbott, AstraZeneca, and Terumo, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Biosensors, and Idorsia, and grants from Medicure. Dr Varenne reports receiving consulting and research grants from Boston Scientific, Abbott Vascular, AstraZeneca, and Servier. Dr Yeh reports consulting and research grants from Abbott Vascular and Boston Scientific, research grants from Abiomed and AstraZeneca, and consulting fees from Biosense Webster, Medtronic, and Teleflex. Dr Krucoff reports receiving consulting and research grants from Abbott Vascular, Biosensors, Boston Scientific, Cook Medical, Medtronic, and OrbusNeich. Dr Morice is the chief executive officer of the Cardiovascular European Research Center, the contract research organization organizing the ARC-HBR initiative. The other authors report no conflicts., Kyoto University [Kyoto], Cardiology, Prémilleux, Annick

    المصدر: Urban, Philip; Mehran, Roxana; Colleran, Roisin; Angiolillo, Dominick J; Byrne, Robert A; Capodanno, Davide; Cuisset, Thomas; Cutlip, Donald; Eerdmans, Pedro; Eikelboom, John; Farb, Andrew; Gibson, C Michael; Gregson, John; Haude, Michael; James, Stefan K; Kim, Hyo-Soo; Kimura, Takeshi; Konishi, Akihide; Laschinger, John; Leon, Martin B; ... (2019). Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European heart journal, 40(31), pp. 2632-2653. Oxford University Press 10.1093/eurheartj/ehz372 <http://dx.doi.org/10.1093/eurheartj/ehz372>
    European Heart Journal
    European Heart Journal, 2019, 40 (31), pp.2632-2653. ⟨10.1093/eurheartj/ehz372⟩
    Urban, Philip; Mehran, Roxana; Colleran, Roisin; Angiolillo, Dominick J; Byrne, Robert A; Capodanno, Davide; Cuisset, Thomas; Cutlip, Donald; Eerdmans, Pedro; Eikelboom, John; Farb, Andrew; Gibson, C Michael; Gregson, John; Haude, Michael; James, Stefan K; Kim, Hyo-Soo; Kimura, Takeshi; Konishi, Akihide; Laschinger, John; Leon, Martin B; ... (2019). Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk. Circulation, 140(3), pp. 240-261. Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.119.040167 <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.040167>
    European Heart Journal, Oxford University Press (OUP): Policy B, 2019, 40 (31), pp.2632-2653. ⟨10.1093/eurheartj/ehz372⟩
    European Heart Journal, 40(31), 2632-2653. Oxford University Press
    Circulation 3 (140), 240-261. (2019)

    وصف الملف: application/pdf

  5. 5
  6. 6

    المساهمون: Cardiology, ACS - Heart failure & arrhythmias

    المصدر: Cardiology journal, 23(6), 626-636. Via Medica
    Ghione, Matteo; Wykrzykowska, Joanna J; Windecker, Stephan; Serruys, Patrick W; Buszman, Pawel; Linke, Axel; Sohn, Hae Young; Corti, Roberto; Antoni, Diethmar; Wijns, William; Estevez-Loureiro, Rodrigo; Morice, Marie-Claude; Van Es, Gerrit-Anne; van Geuns, Robert Jan; Juni, Peter; Eerdmans, Pedro; De Vries, Ton; Konik, Stéphanie; Di Mario, Carlo (2016). Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial. Cardiology journal, 23(6), pp. 626-636. Via Medica 10.5603/CJ.a2016.0071 <http://dx.doi.org/10.5603/CJ.a2016.0071>
    Cardiology Journal, 23(6), 626-636. Via Medica

    وصف الملف: application/pdf

  7. 7
  8. 8

    المساهمون: Cardiology, Radiology & Nuclear Medicine, University of Zurich

    المصدر: EuroIntervention, 6(8), 928-935. EuroPCR
    Garg, Scot; Wykrzykowska, Joanna; Serruys, Patrick W; de Vries, Ton; Buszman, Pawel; Trznadel, Stanislaw; Linke, Axel; Lenk, Karsten; Ischinger, Thomas; Klauss, Volker; Eberli, Franz; Corti, Roberto; Wijns, William; Morice, Marie-Claude; di Mario, Carlo; Tyczynski, Pawel; van Geuns, Robert Jan; Eerdmans, Pedro; van Es, Gerrit-Anne; Meier, Bernhard; ... (2011). The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention, 6(8), pp. 928-935. Toulouse: Europa Digital & Publishing

    وصف الملف: application/pdf

  9. 9
  10. 10
  11. 11

    المساهمون: Cardiology, Radiology & Nuclear Medicine

    المصدر: Barlis, Peter; Regar, Evelyn; Serruys, Patrick W; Dimopoulos, Konstantinos; van der Giessen, Willem J; van Geuns, Robert-Jan M; Ferrante, Giuseppe; Wandel, Simon; Windecker, Stephan; van Es, Gerrit-Anne; Eerdmans, Pedro; Jüni, Peter; di Mario, Carlo (2010). An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. European Heart Journal, 31(2), pp. 165-176. Oxford: Oxford University Press 10.1093/eurheartj/ehp480 <http://dx.doi.org/10.1093/eurheartj/ehp480>
    European Heart Journal, 31(2), 165-176. Oxford University Press

    وصف الملف: application/pdf

  12. 12

    المساهمون: Cardiology, Radiology & Nuclear Medicine

    المصدر: American Journal of Cardiology, 105(4), 475-479. Elsevier Inc.

  13. 13

    المساهمون: Cardiology, University of Zurich

    المصدر: EuroIntervention, 6(2), 233-239. EuroPCR
    Garg, Scot; Sarno, Giovanna; Serruys, Patrick W; de Vries, Ton; Buszman, Pawel; Linke, Axel; Ischinger, Thomas; Klauss, Volker; Eberli, Franz; Corti, Roberto; Wijns, William; Morice, Marie-Claude; Di Mario, Carlo; van Geuns, Robert Jan; Eerdmans, Pedro; van Es, Gerrit-Anne; Meier, Bernhard; Jüni, Peter; Windecker, Stephan (2010). The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention, 6(2), pp. 233-239. Toulouse: Europa Digital & Publishing

    وصف الملف: LEADERS_12_months.pdf - application/pdf; LEADERS_12_months_epub_2010.pdf - application/pdf; application/pdf

  14. 14

    المساهمون: Cardiology, Radiology & Nuclear Medicine, University of Zurich, Windecker, S

    المصدر: Lancet (UK), 372(9644), 1163-1173. Elsevier Ltd.

  15. 15